261 results on '"Gade, T"'
Search Results
52. 4:21 PM Abstract No. 32 Quantitation of hepatic fibrosis by ultrasound in diethylnitrosamine-induced rat model of hepatocellular carcinoma
53. 4:21 PM Abstract No. 270 Iatrogenic celiac axis and hepatic artery dissections during intra-arterial regional tumor therapies: a 16-year retrospective review
54. Abstract No. 530 Association of radiological complete response following locoregional therapy prior to liver transplantation with long-term outcomes of hepatocellular carcinoma patients
55. 4:00 PM Abstract No. 348 Epigenetic alterations enable hepatocellular carcinoma cell survival under metabolic stress
56. 3:36 PM Abstract No. 316 Developing TACE 2.0: targeting hepatocellular carcinoma epigenetic and ischemia survival pathways
57. Abstract No. 528 Antivascular ultrasound (AVUS) demonstrates vascular disruption in a dose-dependent manner in a DEN rat model of hepatocellular carcinoma
58. Abstract No. 514 Injectable thermo-sensitive hydrogels as chemoembolic drug delivery agents for interventional applications
59. 3:00 PM Abstract No. 342 Rapid coaxial probe electrochemical (CoPE) ablation device iteration using computer-aided design (CAD) and 3D printing
60. 3:09 PM Abstract No. 62 Retrospective comparison of outcomes and associated complications between large-bore radiologically inserted gastrostomy tube types
61. 3:09 PM Abstract No. 333 Treatment approach for percutaneous ablation of metastatic adrenal masses
62. Abstract No. 496 Electrochemical treatment causes necrosis by inducing pH changes in the microenvironment
63. 4:12 PM Abstract No. 320 Analysis of in vivo tumor growth kinetics in a diethylnitrosamine-induced, transarterial embolization-treated rat model of hepatocellular carcinoma
64. Endpoints in Locoregional Therapies for Hepatocellular Carcinoma: Continuing Controversy
65. Neoadjuvant locoregional therapy and long-term outcomes of patients with hepatocellular carcinoma listed for orthotopic liver transplantation
66. Development of a novel bispecific antibody for targeted immunotherapy of hepatocellular carcinoma
67. Preliminary characterization of a novel coaxial electrochemical ablation device
68. Women in IR: Are we making an impact?
69. HCC screening behavior and IR interventions at a tertiary transplant center
70. Optical molecular imaging of glypican-3 in hepatocellular carcinoma
71. Geospatial mapping of interventional radiology physician density
72. Optimization of a translational rat model of hepatocellular carcinoma and transarterial embolization
73. Comparison of techniques for establishment and propagation of primary cultured cell lines from hepatocellular carcinoma core needle biopsy samples
74. Characterization of the immune response in murine HCC after AVUS
75. Delayed hepatotoxicity of Y-90 radioembolization
76. Complication rates of percutaneous biliary drainage in the presence of ascites
77. Comparison of infection rates in patients with prior biliary interventions undergoing hepatic embolotherapy treated with single-drug moxifloxacin versus multi-drug antibiotic prophylaxis
78. Exploiting the epigenetic alterations in HCC to enhance TACE: the role of fructose-1,6-bisphosphatase 1 (FBP1) and inhibition of hypoxia inducible factor (HIF)
79. Endoscopic findings after embolization for upper gastrointestinal hemorrhage
80. US HCC screening behavior before and after implementation of a structured reporting initiative
81. ▪ FEATURED ABSTRACTNeoadjuvant transarterial chemoembolization (TACE) of cirrhotomimetic hepatocellular carcinoma: outcomes and comparison to non-cirrhotomimetic hepatocellular carcinoma
82. Targeting the metabolic stress response in hepatocellular carcinoma through inhibition of the unfolded protein response
83. Durability of improved renal function following PTFE covered TIPS for refractory ascites
84. DISTINGUISHED ABSTRACT Near infrared fluorescence imaging of matrix metalloprotease activity as a biomarker of vascular remodeling in hemodialysis access
85. Comparison of complication rates between palliative and curative intent lung ablations
86. The interventional radiologist’s role in precision medicine
87. Baseline MR apparent diffusion coefficient quantification as a response predictor of unresectable hepatocellular carcinoma to Therasphere® yttrium-90 radioembolization
88. Abstract No. 534 - Women in IR: Are we making an impact?
89. Abstract No. 489 - Comparison of infection rates in patients with prior biliary interventions undergoing hepatic embolotherapy treated with single-drug moxifloxacin versus multi-drug antibiotic prophylaxis
90. Abstract No. 418 - Comparison of techniques for establishment and propagation of primary cultured cell lines from hepatocellular carcinoma core needle biopsy samples
91. Abstract No. 378 - Delayed hepatotoxicity of Y-90 radioembolization
92. Abstract No. 361FEATURED ABSTRACT - Geospatial mapping of interventional radiology physician density
93. Abstract No. 243 - Preliminary characterization of a novel coaxial electrochemical ablation device
94. Abstract No. 219 - HCC screening behavior and IR interventions at a tertiary transplant center
95. Abstract No. 133 - Characterization of the immune response in murine HCC after AVUS
96. Abstract No. 132 - Optical molecular imaging of glypican-3 in hepatocellular carcinoma
97. Abstract No. 130 - Exploiting the epigenetic alterations in HCC to enhance TACE: the role of fructose-1,6-bisphosphatase 1 (FBP1) and inhibition of hypoxia inducible factor (HIF)
98. Abstract No. 135 - Optimization of a translational rat model of hepatocellular carcinoma and transarterial embolization
99. Abstract No. 129 - Development of a novel bispecific antibody for targeted immunotherapy of hepatocellular carcinoma
100. Abstract No. 121 - Complication rates of percutaneous biliary drainage in the presence of ascites
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.